This is an editorial summary of research originally reported by The Lancet. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
Free weekly digest
We track health and safety research on food, cosmetics, and household products and send you what matters. Join 27 readers.
What would you like to do next?
I use this product
Get the next safety alert before it goes viral
Free weekly digest of health findings about everyday products. No spam, unsubscribe any time.
Advertisement
Get the latest health findings delivered to your inbox. Only the important stuff. No spam.
We'll send a confirmation email. Unsubscribe anytime.
Adults who stop taking tirzepatide after weight loss tend to regain the weight, but continuing the drug keeps the weight off and protects heart health. A lower dose of 5 mg might work for some people who can't tolerate higher doses, though results vary by individual. This shows that obesity treatment needs to be ongoing, not just short-term.
A major clinical trial has tested whether people with obesity can maintain their weight loss after taking tirzepatide, a newer obesity medication. The study, called SURMOUNT-MAINTAIN, tracked adults who had already lost weight on the drug. Researchers wanted to know what happened when people either continued the medication, reduced their dose, or stopped taking it altogether. The findings are important because obesity treatment often fails when people regain weight after their medication ends.
The trial found that people who kept taking tirzepatide at their regular dose successfully maintained their weight loss and the health benefits that came with it. These benefits included improvements in heart and metabolic health. The research also showed that dropping down to a lower dose of 5 mg could be a middle-ground option for some patients. However, the results weren't identical for everyone. Different people responded differently to dose changes, suggesting that treatment needs to be tailored to each individual.
These results highlight a key lesson about obesity treatment. Unlike short-term diets, managing obesity often requires ongoing medication. Stopping treatment tends to lead to weight regain and loss of the health improvements people gained. The study suggests that people shouldn't expect to take tirzepatide for a few months and then be done. Instead, staying on the medication long-term appears necessary to keep the weight off.
If you're considering tirzepatide or are already taking it, talk openly with your doctor about your treatment plan. Ask about how long you might need to stay on the medication and whether a lower dose could work for you. Weight management is personal, and your doctor can help you find the approach that fits your health goals and lifestyle. Don't assume that losing weight means you can stop treatment. The evidence shows that ongoing therapy gives you the best chance of keeping that weight off.
Always consult a healthcare professional for personal medical advice.
Read the full report at the original source
The LancetWas this finding useful?
Community discussion
Join the discussion
Comments are reviewed before appearing publicly.